Home › Decisions › HALO 2026-03-05

HALO FDA decision — Mar 5, 2026

✓ APPROVED

Halozyme Therapeutics Inc. — TECVAYLI (teclistamab-cqyv) and DARZALEX FAS · Relapsed/refractory multiple myeloma (RRMM).

Run-up into the decision (T-120 → T+5)

Daily close, T-120 (9/18/25) through T+5. Run-up high $81.23 on 2/9/26, low $61.87 on 12/15/25 (T-120 to T-1). FDA decision 3/5/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-05

OutcomeApproved

Drug / candidateTECVAYLI (teclistamab-cqyv) and DARZALEX FAS

CompanyHalozyme Therapeutics Inc.

120-day run-up (T-120→T-1)-9.7%